<DOC>
	<DOCNO>NCT00004061</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use growth factor may effective reduce side effect patient hematologic cancer receive radiation therapy , chemotherapy , peripheral stem cell transplantation . PURPOSE : Randomized phase II trial study effectiveness biological therapy reduce side effect patient undergo radiation therapy , chemotherapy , peripheral stem cell transplantation treat lymphoma leukemia .</brief_summary>
	<brief_title>Biological Therapy Treating Patients Undergoing Radiation Therapy , Chemotherapy , Peripheral Stem Cell Transplantation Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy recombinant human keratinocyte growth factor ( rHuKGF ) reduce severe oral mucositis induce total body irradiation high dose chemotherapy patient hematologic malignancy . II . Compare incidence severe oral mucositis , use transdermal perenteral opioid analgesic , incidence duration grade 2-4 diarrhea without rHuKGF patient . III . Determine quality life patient . IV . Determine duration febrile neutropenia duration treatment intravenous antifungal antibiotic patient . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord center . Patients randomize one three treatment arm . Arm I : Patients receive recombinant human keratinocyte growth factor ( rHuKGF ) IV day -11 -9 , -5 , 0 2 . Total body irradiation ( TBI ) administer twice day day -8 -5 . Patients receive etoposide IV 4 hour day -4 cyclophosphamide IV 1 hour day -2 ( patient may receive alternate regimen ifosfamide IV 1 hour days-4 0 follow day etoposide IV 23 hour ) . Filgrastim ( G-CSF ) administer subcutaneously ( SQ ) begin day 0 continue 21 day blood count recover . Autologous peripheral blood stem cell ( PBSC ) infuse day 0 . Arm II : Patients receive rHuKGF day -11 -9 -5 arm I . Placebo administered day 0 2 . TBI , chemotherapy , PBSC transplantation administer arm I . Arm III : Patients receive placebo day -11 -9 , -5 , 0 2 . TBI , chemotherapy , PBSC transplantation administer arm I . Quality life assess prior treatment , daily therapy day 28 transplantation . Patients follow day 28 approximately day 60-100 . PROJECTED ACCRUAL : At least 111 patient ( 37 per arm ) accrue study within 15 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : NonHodgkin 's lymphoma Hodgkin 's disease Acute myelogenous leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia Chronic lymphocytic leukemia Eligible fractionate total body irradiation plus high dose chemotherapy follow autologous peripheral blood stem cell support No prior entry study PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Karnofsky 70100 % SWOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : DLCO least 60 % predict Other : No prior concurrent malignancy No active infection oral mucositis No diabetes mellitus require insulin HIV negative No sensitivity E. coli derive product Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior bone marrow peripheral blood stem cell transplantation No concurrent interleukin11 Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior extensive radiotherapy would preclude study irradiation Surgery : Not specify Other : At least 30 day since prior investigational study No concurrent investigational agent No concurrent prophylactic oral cryotherapy study chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>oral complication</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>